What is your current role on AMYPAD?
I am WP4 lead and that entitles me to be part of the ExCom leadership as well. I am also the principal investigator for the Diagnostic Study. As a WP4 lead, I am in charge of enabling WP4 to conduct the Prognostic Study. We are making a huge effort right now because we realised that we didn’t have a sufficient number of participants just with EPAD, so we are allowing non-EPAD cohorts to be part of the project.
What is your overall vision?
I think AMYPAD is a key project to understand the role of amyloid imaging both for the clinical diagnosis of Alzheimer’s disease and its relevance for diagnostic confidence and also from a health and economic perspective. On the other hand, we have to understand the role in the early stages, and that is what the Prognostic Study is going to answer. In my opinion, AMYPAD is going to show how relevant amyloid imaging is in the Alzheimer’s disease continuum both to understand the very early stages and, later on, the value for diagnosis.
What do you find most challenging about the project?
The greatest challenge in AMYPAD is its size and complexity. We are dealing with a large number of participants and a lot of complexities: multicentre project, thousands of participants to be involved, and developed as clinical trials. These factors always require a great deal of both commitment and a perfectly organized system to be able to get the answers that we need. It always takes a long time to organize things before we can run them. But I think we are there now, so it should be fun and smooth!